Clinical trials: Preventable Disease, Vaccine
Pneumococcal Infections, Chronic Lymphocytic Leukemia
Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia
In this study the antibody response after vaccination with the 13-valent pneumococcal conjugated vaccine (PCV13) followed 2 months later by the 23-valent polysaccharide vaccine (PPSV23) in adults with chronic lymphocytic leukemia…
- Conditions
- Pneumococcal Infections, Chronic Lymphocytic Leukemia, Vaccine-Preventable Diseases, Invasive Pneumococcal Disease, Recurrent Isolated
- Trial name
- Pneumo-CLL (NCT05145101)
- Testing
- Prevnar13
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Hannah Garcia Garrido
Influenza
Project IMPACT Immunizations (IMProving America's Communities Together) Scaled Demonstration
The primary objective of this study is to evaluate how implementing an innovative care model that provides the pharmacist access to a patient's vaccine history at the point-of-care impacts the pharmacist's ability to identify…
- Trial name
- NCT03372967
- Testing
- Vaccine administration by a pharmacist, Unmet vaccination needs identified and met, Vaccination forecast review and patient education
- Where
- 22 sites in United States
- Volunteers
- 6,234 people, healthy volunteers welcome
- Sponsor
- American Pharmacists Association Foundation
Vaccine-Preventable Diseases, Hepatitis B
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine
The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-HBV-002.
- Trial name
- CVI-HBV-002 (NCT06147895)
- Testing
- CVI-HBV-002
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Aribio Lab Co., Ltd.
Vaccine Refusal, Vaccine-Preventable Diseases
Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters
Unfortunately, only 40% of US pediatric residency programs reported in a survey that vaccine safety and counseling training is provided to residents.
- Conditions
- Vaccine Refusal, Vaccine-Preventable Diseases, Physician-Patient Relations
- Trial name
- NCT06074237
- Testing
- Immersive resident education, Standardized patient (SP) encounter
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Corewell Health East
Vaccine Preventable Diseases, Meningococcal Disease
Testing the Use of Prompts to Increase Adolescent Immunization Rates
Although most US adolescents visit their primary care doctor, their immunization rates are low. Primary care practices from two networks, one in upstate New York as well as a national network of pediatric clinics were surveyed to…
- Conditions
- Vaccine Preventable Diseases, Meningococcal Disease, Human Papillomavirus, Pertussis
- Trial name
- AIMHi (NCT01984125)
- Testing
- Point-of-Care Prompt
- Where
- 22 sites in United States
- Volunteers
- 7,040 people
- Sponsor
- University of California, Los Angeles
COVID-19, Vaccine Adverse Reaction
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
The objective of this observational case-crossover study is to evaluate the effectiveness, safety and immunogenicity of the second booster dose in the elderly.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases
- Trial name
- Plus_Booster (NCT05283902)
- Testing
- ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine
- Where
- Brazil
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Federal University of Espirito Santo
Vaccine-Preventable Diseases
An Evaluation of a Dynamic Web-Based Visualization of Community Immunity
This study is a PhD project conducted by Ms. Hina Hakim, supervised by Dr. Holly O. Witteman, PhD, and co-supervised Dr. Daniel Reinharz, professors and researchers at the Faculty of Medicine at Laval University.
- Trial name
- NCT04787913
- Testing
- herdimm, guardianmeasles, theotheredmundmeasles
- Where
- Canada
- Volunteers
- 5,516 people, healthy volunteers welcome
- Sponsor
- Laval University
Hepatitis B, Vaccination; Infection
The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs…
- Conditions
- Hepatitis B, Vaccination; Infection, Preventable Disease, Vaccine
- Trial name
- IRHBRVD (NCT04970836)
- Testing
- recombinant hepatitis B vaccine
- Where
- Taiwan
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Hepatitis A, Hepatitis A Virus
Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV
Hepatitis A virus (HAV) remains a common infection in Thai children. Two HAV vaccines are available: inactivated vaccine (I-HAV, 2 doses) and live-attenuated vaccine (L-HAV, single dose), but neither is included in Thailand's…
- Conditions
- Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases
- Trial name
- HAV-2 (NCT06978621)
- Testing
- Inactivated hepatitis A vaccine (I-HAV)
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
Health Care Utilization, Vaccine Preventable Disease
Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination
Our objective is to determine the effectiveness of varied outreach methods to children age 12-17 years old who are due for a well child check visit and don't have one scheduled in the next 45 days on the outcomes of appointment…
- Trial name
- NCT04904744
- Testing
- Low tailored message, No message, Low tailored message plus COVID-19 vaccine message
- Where
- United States
- Volunteers
- 1,235 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Iron Deficiency Anemia, Vaccine Response Impaired
Iron and COVID-19 Vaccine Response
Vaccines often underperform in Africa compared to high-income countries. Why vaccines do not work as well in Africa remains uncertain. Malnutrition likely plays a role.
- Conditions
- Iron Deficiency Anemia, Vaccine Response Impaired, COVID-19 Vaccine, Iron Deficiency Anemia Treatment
- Trial name
- NCT04915820
- Testing
- Ferinject
- Where
- Kenya
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Jomo Kenyatta University of Agriculture and Technology
HPV Infection, Vaccine-Preventable Diseases
Game-Based Intervention to Promote HPV Vaccination
This study will examine the feasibility and acceptability of an innovative game-based intervention designed for families of youth aged 11-14 to promote HPV vaccination; will explore changes in key outcomes and related measures…
- Trial name
- NCT06162676
- Testing
- HPV game
- Where
- United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Michigan State University
Human Papilloma Virus, Vaccine-Preventable Diseases
Hashtag HPV: HPV Vaccine Twitter Education Program
Parents use social media as an important parenting tool and source for health information. Using social media data to examine public opinion has had an early impact in public health and in cancer control and prevention efforts…
- Trial name
- NCT05204030
- Testing
- HPV Twitter Education Program - Narrative, HPV Twitter Education Program - Non-Narrative
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Arkansas, Fayetteville
Vaccine-Preventable Diseases
Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity
Rationale Causing a wide range of infectious diseases, including pneumonia, otitis media and meningitis, S. pneumoniae represents an important global health problem.
- Trial name
- SEA (NCT06202703)
- Testing
- Pneumococcal Vaccine
- Where
- Netherlands
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Vaccine Preventable Disease
Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations
A cluster randomized trial will be conducted prior to widespread vaccine availability to the general public. Community-informed COVID-19 vaccine messages will be disseminated to participants.
- Trial name
- CERC (NCT04765839)
- Testing
- Educational, culturally appropriate COVID-19 messages
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
COVID-19, Vaccine-Preventable Diseases
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
- Trial name
- SHIELD (NCT06633835)
- Testing
- protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novavax
Streptococcus Pneumonia, Vaccine Preventable Disease
Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age
The current study provides data necessary to evaluate the safety and immunogenicity of Serum Institute of India's PNEUMOSIL® [Pneumococcal Polysaccharide Conjugate Vaccine Adsorbed (10-Valent)] in Healthy Vietnamese Infants and…
- Trial name
- PNEUMOSIL (NCT05140720)
- Testing
- PNEUMOSIL®
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Vabiotech
Multiple Sclerosis
Immunisation Status and Safety of Vaccines in Italian MS Patients
Multiple sclerosis (MS) patients are more susceptible to infections than the general population in relation to some specific therapies or increasing disability.
- Trial name
- NCT04300868
- Where
- Italy
- Volunteers
- 3,000 people
- Sponsor
- Monica Ulivelli
AIDS/HIV - RelatedDisease Associated With AIDS, Vaccine-Preventable Diseases
Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.
This is a first in human testing of novel HIV-1 protein nanoparticles vaccine candidates, UVAX-1107 and UVAX-1197 mixed with Aluminum Hydroxide (AH) and CpG 1018 adjuvants.
- Conditions
- AIDS/HIV - RelatedDisease Associated With AIDS, Vaccine-Preventable Diseases, HIV Infections
- Trial name
- NCT06541093
- Testing
- UVAX-1107, UVAX-1197
- Where
- Australia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Uvax Bio LLC
Vaccine-Preventable Diseases, Herpes Zoster
Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.
- Trial name
- NCT06137755
- Testing
- CVI-VZV-001, Shingrix
- Where
- 2 sites in South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Aribio Lab Co., Ltd.